Trump Weighs Brenner and Vacirca for FDA Posts

The administration is considering two candidates for FDA leadership after the commissioner nomination was withdrawn.

Updated on Nov. 21, 2026 in People

Trump Weighs Brenner and Vacirca for FDA Posts

Live Poll

Do you trust the federal government to run the FDA well?

The Trump administration is considering Sara Brenner, a senior adviser at the Department of Health and Human Services, and Jeff Vacirca, head of New York Cancer & Blood Specialists, for FDA leadership positions. Final staffing decisions have not been made, and a White House official said any reporting before announcements is speculation.

Why it matters

The FDA is led on a temporary basis after Marty Makary resigned in May and Heidi Overton's commissioner nomination was withdrawn. Several of the agency's top positions, including the second-in-command deputy, are vacant, and the FDA regulates products accounting for roughly a fifth of U.S. consumer spending.

FDA-regulated products account for roughly a fifth of U.S. consumer spending, and Makary served one year before resigning in May. Final staffing decisions have not been made.

The players

Sara Brenner

Brenner is a physician and senior adviser at the Department of Health and Human Services, serving as senior counselor for public health, and is among the candidates under consideration for FDA leadership.

Jeff Vacirca

Vacirca is the CEO and chairman of New York Cancer & Blood Specialists, a position he has held since 2008, and is under consideration for FDA leadership after an interview with President Trump.

Heidi Overton

Overton was nominated as FDA commissioner, but her nomination was withdrawn on Tuesday, leaving the agency's top post open.

Marty Makary

Makary resigned as FDA commissioner in May after one year in the role, a tenure marked by clashes with staff.

Kyle Diamantas

Diamantas is leading the FDA on a temporary basis and is expected to depart by the end of the year.

The details

President Donald Trump interviewed Vacirca for the commissioner role in August, according to people familiar with the matter. Brenner is a physician and senior counselor for public health at HHS, while Vacirca has served as CEO and chairman of New York Cancer & Blood Specialists since 2008.

Timeline

  1. May: Marty Makary resigned as FDA commissioner.

  2. August: Trump interviewed Vacirca for the commissioner role.

  3. Tuesday (November 2026): Heidi Overton's nomination as commissioner was withdrawn.

  4. End of 2026: Kyle Diamantas is expected to depart FDA leadership.

Market Landscape

The leadership search follows a run of turnover at the agency that began with Makary's May resignation and the withdrawal of Overton's nomination. The next leaders will be charged with advancing efforts to speed clinical trials and overhaul drug reviews for rare diseases.

Leadership changes at the FDA can affect the timing of drug and device reviews that reach American patients and consumers. Staffing gaps in top posts, including the second-in-command deputy, may slow decisions on products Americans use daily.

The takeaway

Leadership vacancies at a regulator touching roughly a fifth of consumer spending make the pending FDA appointments worth watching. Readers should track official announcements, since the White House has said reports before them are speculation.

What happens next

Kyle Diamantas is expected to depart FDA leadership by the end of 2026, which will open another leadership transition at the agency.

Further reading

Explore more People coverage to see how leadership changes shape major federal agencies.

Source note: This article includes information reported by The Brunswick News.

Live Poll

Do you trust the federal government to run the FDA well?